Global Health reported a standalone net profit of ₹1,373.07 million for the quarter ended June 30, 2026, a decline from ₹1,519.64 million in Q1FY26, even as revenue from operations rose 22% year-on-year to ₹10,787.23 million. On a consolidated basis, net profit stood at ₹1,572.52 million, broadly in line with ₹1,589.82 million in the prior year period, while consolidated revenue grew to ₹13,040.51 million from ₹10,308.44 million. Alongside the financial results, the Board approved a significant capacity expansion at its upcoming Guwahati hospital and appointed a new Chief Digital Officer to lead digital transformation initiatives.

The Board meeting held on July 30, 2026, was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory Auditors M/s Walker Chandiok & Co LLP issued limited review reports on both standalone and consolidated results pursuant to Regulation 33. The trading window for designated directors will open 48 hours after the declaration of these results.

Financial Performance

Revenue growth was driven by increased patient inflow and service utilization, though higher employee benefits and finance costs impacted profitability margins. Consolidated EBITDA rose to ₹2.9 billion from ₹2.27 billion year-on-year, with EBITDA margin holding steady at 22% in both periods. The following table summarises key financial metrics for the quarter:

Employee benefits expense rose to ₹2,854.73 million (standalone) and ₹3,192.73 million (consolidated), reflecting ongoing investments in human capital. Finance costs also increased, with standalone finance costs reaching ₹158.90 million compared to ₹56.58 million in the prior year quarter.

Strategic Expansions and Appointments

The Board approved a revised construction plan for the company's upcoming hospital in Guwahati, increasing the proposed bed capacity from 400 to 650 beds. The project, estimated at ₹970 crore, will be funded through internal accruals and debt. This expansion aims to serve over 50 million people across Assam and neighboring states, addressing the high burden of non-communicable diseases in the region with limited tertiary care facilities.

Additionally, the company appointed Mr. Pradeep Kumar Singh as Chief Digital Officer and Senior Management Personnel, effective July 30, 2026. With over 25 years of experience in technology leadership and digital transformation, Mr. Singh holds an M.Tech. from IIT Roorkee and a B.Tech. from the Institute of Engineering and Technology, Lucknow.

Dividend and Corporate Actions

Pursuant to Regulation 42 of the Listing Regulations, the company fixed August 14, 2026, as the record date for determining shareholder entitlement for the final dividend for FY26. The proposed dividend is ₹0.50 per equity share, subject to approval by shareholders at the 22nd Annual General Meeting scheduled for September 16, 2026.

What the Numbers Show

While top-line growth remained robust at 22% year-on-year and EBITDA expanded meaningfully to ₹2.9 billion, the EBITDA margin holding flat at 22% indicates that cost pressures offset operational scale benefits. The divergence between revenue growth and standalone net profit contraction highlights ongoing margin pressure from rising employee benefits and finance costs. The absence of exceptional items in Q1FY27, unlike the ₹195.92 million EPCG reversal benefit seen in Q1FY26, also contributed to the lower bottom line, indicating that core operational profitability needs closer monitoring as the company scales its infrastructure.

The Nomination and Remuneration Committee of global health approved the grant of 20,000 Employee Stock Options (ESOPs) to one employee on July 30, 2026. The grant was made under Part A of the Global Health Limited Employees Long Term Share Based Incentive Plan 2024, known as the GHL LTIP 2024 Plan. This move aligns with the company’s strategy to attract, retain, and motivate key talent by linking employee rewards to corporate growth and profitability.

The committee meeting commenced at 11:00 A.M. and concluded at 11:35 A.M. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rahul Ranjan, Company Secretary & Compliance Officer, signed the intimation submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited.

Grant Details

The specific terms of the ESOP grant are outlined below:

Each option granted will result in the allotment of one equity share of ₹2 face value upon exercise. The scheme is compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Strategic Context

The GHL LTIP 2024 Plan is designed to reward employees for their association, dedication, and contribution to the company’s goals. Management views the ESOP scheme as a long-term incentive tool that enables employees to become co-owners and create wealth through ownership. The vesting schedule and conditions are detailed in the individual grant letters issued to the recipient.

No options have been vested, exercised, or lapsed at this stage. The diluted earnings per share impact has not been calculated as no exercise has occurred.